Sabinsa’s Forskolin Gets China Solubility Patent

December 20, 2010

Sabinsa Corp. (East Windsor, NJ) has received a solubility patent for forskolin, a Coleus forskohlii extract, from the People’s Republic of China.

Sabinsa Corp. (East Windsor, NJ) has received a solubility patent for forskolin, a Coleus forskohlii extract, from the People’s Republic of China. The patent is titled “Process for Preparing Water Soluble Diterpenes and Their Applications.”

Sabinsa’s technology allows it to make the forskolin molecule water soluble by approximately 6000 times, vastly increasing the ingredient’s application range.

“Aqueous formulation facilitates the safe and effective use of forskolin as a natural ophthalmic drug in the management of glaucoma (approved in India), as well as in dermatological and related applications,” says Dr. Lakshmi Prakash, vice president of innovation and business development.

Sabinsa says that in recent years, forskolin has gained recognition for its health and wellness applications, in part due to Sabinsa’s research on the ingredient.

Sabinsa also holds patents on forskolin solubility in the United States, Eurasia, India, Phillipes, Mexico, New Zealand, Singapore, South Africa, and Uzbekistan.